Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
AIM ImmunoTech Board Issues Letter to Shareholders
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders
AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference
AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4
5
6
7
8
9
10
11
12
13
14
<<
<
>
>>
Privacy